Kornimate/medical-research-clean huggingface dataset:
the effect of a self-rehabilitation program in addition to usual treatment for spasticity on impairment and activity limitation in patients with spastic hemiparesis following stroke

Conditions: Spastic Hemiparesis

Summary: the addition of a self-rehabilitation program to repeated botulinum toxin injections (bti) and usual physiotherapy should increase the proportion of patients who attain their primary treatment goal (impairments and function) more than usual care (involving repeated botulinum toxin injections and conventional physiotherapy), in post stroke out-patients with spasticity.

stroke affects 150 000 persons in france each year. most patients have activity limitations because of the resulting motor deficit and spasticity. autonomy in activities of daily living is reduced. the principal treatment for focal spasticity is currently intramuscular botulinum toxin injection (bti). bti is classically combined with only 2 to 3 sessions of out-patient physiotherapy per week. this is mainly because of a lack of out-patient therapists. however, this amount of therapy is insufficient and does not follow current literature which shows that the intensity of physiotherapy affects the recovery of impairment and activity. this gap in our health system could be filled by a self-rehabilitation program in addition to physiotherapy. recent studies have shown that self-rehabilitation following bti could significantly improve activity limitation (roche et al, 2014 ; sun et al 2010). the addition of a self-rehabilitation program to bti and usual out-patient physiotherapy could thus increase the effects of bti on impairment and activity limitation in patients with spastic hemiparesis following stroke.

Eligibility criteria:
inclusion criteria: 1. males and females aged between 18 to 75 years. 2. adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained. 3. single stroke having occurred more than 6 months before (previous tia is accepted). 4. capable of understanding instructions and participating in the definition of a therapeutic goal (boston diagnostic aphasia examination (bdae) \< 3). 5. having previously undergone bti. the last injection must have been performed at least 4 months prior to inclusion. 6. affiliation to the french social security regime or a similar regime. 7. patient (or the legal guardian if under guardian adult patient) has signed the informed consent form. exclusion criteria: 1. patients who are unwilling to participate in the study. for the one under guardianship, the refusal of the patient will be the final decision even if the guardian is willing to participate. 2. subjects who are unlikely to adhere to the study an/or poor adherence anticipated by the investigator. 3. un-controlled progressive pathology. 4. osteoarticular lesion which contraindicates part of the rehabilitation involved in the study. 5. patients with other interventions planned prior to the end of the study period (orthosis, surgery etc.). 6. surgery to the treated limb less than 6 months previously. 7. pregnant woman.

Keywords: spastic hemiparesis stroke self-rehabilitation botulinum toxin injections
angina in non coronary artery disease

Conditions: Angina Pectoris; Microvascular Angina; Angina Pectoris, Variant

Summary: many patients undergoing coronary angiography are found to have no significant coronary artery disease (cad) despite angina equivalent symptoms and/or electrocardiographic abnormalities suggestive of myocardial ischemia. the aim of this study is to systematically assess patients with angina equivalent symptoms despite normal coronary angiograms and to evaluate their symptoms according to a defined algorithm.

all consecutive patients who had coronary angiography at the luzerner kantonsspital between july 1st 1996 and july 31st 2008 and who had no significant coronary stenoses (no coronary stenoses ≥ 50%) were recruited for this study. patients are extensively examined during angiography using acetylcholine infusion and fast atrial pacing. according to the result of the additional invasive examination (vasospasm, vasoconstriction, vasodilation; symptoms during examination) a distinct diagnosis is attributed to the patients (small vessel disease, vasospastic disease, hypertensive heart disease, rhythm disorder, or extracardiac thoracic pain including pulmonary hypertension). patients are followed-up after 10 years and prognosis of these patients is assessed (including mortality, cardiovascular events, re-angiography, functional status after 10 years).

Eligibility criteria:
inclusion criteria: * coronary angiography at the luzerner kantonsspital between july 1st 1996 and july 31st 2008 * no significant coronary stenoses (no coronary stenoses ≥ 50%) exclusion criteria: * severe valvular heart disease * severe congestive heart failure
assessment of the patients of emergency consultation

Conditions: Demographics of Intubated Patients Due to an Urgent Call

Summary: the demographic data, mortality rates and clinical diagnoses of the patients who were evaluated, intubated and interned to icu by the anesthesiology department due to an urgent consultation call from the emergency department in 2010-2011. primary outcome: an examination of demographic data, predicted mortality rates and the clinical diagnosis of the patients secondary outcome: to determine the terminal cancer ratio inclusion criteria: patients throughout the hole hospital whom was intubated by the anaesthesiology team due to an emergency consultation call exclusion criteria: patients who refused treatment

the demographic data and findings completed in the emergency department were obtained from the patient cards and information related to existing diseases was obtained from the patient records for the cases included in the study. predicted mortality values were calculated for each patient with apache ii and saps ii values using the worst or most critical physiological and laboratory parameters in the first 24 hours in the emergency department.

Eligibility criteria:
inclusion criteria: * patients throughout the hole hospital whom was intubated by the anaesthesiology team due to an urgent consultation call exclusion criteria: * patients who refused treatment

Keywords: intubation intensive care withholding treatment cancer terminal care apache
efficacy study comparing topical m518101 and vitamin d3 in adult psoriasis patients

Conditions: Plaque Psoriasis

Summary: m5181 - a novel vitamin d3 analogue - is currently under development for the treatment of plaque psoriasis and is being developed as a topical ointment formulation (m518101) clinical and non-clinical studies indicate that m5181 is an effective treatment for plaque psoriasis. based on the results of previous phase ii trials the phase iii trial has been designed to evaluate efficacy and safety of an 8-week treatment period with 50 μg/g m518101 in a larger population of patients with stable plaque psoriasis.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or older on the day of signing the informed consent form (icf) * psoriasis patients with up to 20% affected body surface area ( bsa) (not including face or scalp) * investigator global assessment(iga) of moderate to severe and who are suitable for topical therapy exclusion criteria: * pregnant or lactating females; * patients with known allergic reactions, irritations or sensitivity to vitamin d3 derivatives drug hypersensitivity to other components of the investigational products; * patients who have been treated with topical steroids, topical immunosuppressive/ immunomodulative drugs, topical vitamin d3 derivative, topical retinoids, anthralin, coal tar (except when used as shampoo) salicylic acid within 14 days of randomization * patients, who in the opinion of the investigator, have clinically relevant history or presence of any disease, any other skin disorder, any chronic medical condition which is not well controlled or surgical history which may interfere with the conduct of the trial * patients whose calcium test at screening exceed the upper limit of reference range (including serum calcium, albumin, phosphate, parathyroid hormone); * patients who have used any study drug (including experimental biologics) and/or participated in any clinical trial within the last 60 days before the day of randomization * patients who have been treated with any biologics for their psoriasis within 30 days or 5 half-lives (whichever is longer) of the biologic before the day of randomization the longest documented half-life of the biologic should be used to calculate the 5 half-lives; * patients who have been treated with phototherapy (laser, oral steroids, oral retinoid, oral immunosuppressive/immunomodulative drugs, cytostatics, cyclosporine or methotrexate within 30 days of randomization

Keywords: psoriasis vitamin d3 topical ointments
procedural pain in palliative care: prevalence, intensity and treatment

Conditions: Breakthrough Pain; Pain Due to Certain Specified Procedures; Pain; Cancer; Terminal Disease

Summary: this study aims to assess self reported procedural pain compared with background pain and evaluate pain intensity differences across six standard procedures. besides, rescue and preventive treatments used to control procedural pain will be examined.


Eligibility criteria:
inclusion criteria: * patients receiving the procedures included in this study as a part of their standard care * patients that have expressed their consent to participate to the study by signing the informed consent document exclusion criteria: * very serious or unstable clinical conditions with a karnofsky performance status index (kps) \< 20 * presence of neurological or psychiatric conditions, due to the original disease or concomitant diseases, interfering with the patient's level of consciousness or with judgment, such as to compromise compliance with the study protocol; * not adequately controlled background pain (average nrs in the last 24 hours is \> 4) * emergency procedures or procedures performed during night time (from 8 p.m. until 8 a.m)
functional and clinical outcomes of hyaluronic acid and steroid injections in bilateral knee osteoarthritis

Conditions: Osteoarthritis (OA) of the Knee; Osteoarthritis; Osteoarthritis in the Knee; Osteoarthritis of Knee; Osteoarthritis of the Knees; Osteoarthritis of Knee Joint; Osteoarthritis Knee; Osteoarthritis of the Knee

Summary: the aim of this study is to compare functional and clinical outcomes of intraarticular injections of hyaluronic acid and steroids in patients with bilateral knee osteoarthritis. we will compare clinical and functional outcomes for each knee separately after week 6, month 3, month 6, and one year after the intervention.

we will include patients with bilateral knee osteoarthritis (kellgren lawrence grades 2 and 3). on initial examination, we will measure active and passive range of flexion and extension, presence of swelling, joint effusion, vas score for each knee separately, and womac score for every knee separately. we will randomly apply hyaluronic acid injection in one knee and steroid injection in the other knee. we will repeat the same examination after week 6, month 3, month 6, and one year after the procedure. the main aim is to check whether there is a significant clinical or functional difference between two groups.

Eligibility criteria:
inclusion criteria: * bilateral knee pain * same grade of osteoarthritis in both knees * kellgren-lawrence grade 2 or 3 of knee osteoarthritis * fully completed all follow-up examinations exclusion criteria: * unilateral knee osteoarthritis * different grade of osteoarthritis between knees based on kellgren-lawrence scale * positive history of previous knee interventions (injections, surgery) * positive history of additional knee injuries (meniscus, ligament...)

Keywords: osteoarthritis hyaluronic acid steroid injection kellgren lawrence oa arthritis
evaluation of pcv-aco2 in the fluid treatment of abdominal tumor patients after surgery

Conditions: Abdominal Tumor; Abdominal Infection

Summary: this research will confirm that pcv-aco2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic effect of these patients.

1. confirmed that pcv-aco2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic efficacy of this kind of patients. 2. pcv-aco2 effectively reflected the improvement of tissue and organ microcirculation disorder through the individual goal target treatment to guide the fluid resuscitation in the hemodynamic instability patients. 3. research of the correlation between pcv-aco2 and the organ function in patients with abnormal hemodynamics after operation.

Eligibility criteria:
inclusion criteria: 1. acute physiology and chronic health score system ii (apache ii) score ≥10； 2. hemodynamic abnormalities post-operation (a. systolic blood pressure\ 100 / min, e.central venous pressure(cvp) \ 2.7mmol/l, meet any one above). 3. age ≥ 18 years, which is expected to stay in icu for 5 days or longer; 4. patients themselves or their authorized clients agree to participate in clinical trials and signed informed consent. exclusion criteria: 1. age \<18 years; 2. without improvement in respiratory system disease or chronic obstructive pulmonary disease with forced expiratory volume in one second (fev1) \<50%; 3. lobectomy and pneumonectomy; 4. death within 24 after treatment; 5. patients with severe organ dysfunction; 6. pregnant or lactating women; 7. the patients did not sign informed consent; 8. any factors that may be expected to increase the risk of patients or other factors that may interfere with the results of clinical trials.

Keywords: tumor abdominal infection hemodynamics pcv-aco2 early goal-directed therapy (egdt)
a real-world study of donafenib combined with tace-based treatment in patients with unresectable hcc

Conditions: Hepatocellular Carcinoma; Donafenib

Summary: this study is a prospective, single-center, observational real-world study. it is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with donafenib combined with tace-based treatment, so as to observe and evaluate the efficacy and safety of donafenib combined with tace-based treatment in patients with unresectable hcc.


Eligibility criteria:
inclusion criteria: 1. patients voluntarily entered the study and signed informed consent form (icf); 2. age: be at least 18 years old and and there is no limit on the gender; 3. clinically or histologically diagnosed as unresectable hcc; 4. there is at least one measurable lesions that meet the mrecist standard; 5. child-pugh classification a or b (score≤7); 6. the maximum number of tace procedures allowed before enrolment was 2. all of those patients who had a history of prior tace achieved complete response by previous tace, but recurred more than 6 months later at the study entry 7. ecog : 0 \~ 2 ; 8. before the patients were enrolled in the study, doctors had decided to treat them with donafenib in combination with tace. exclusion criteria: 1. donafenib forbidden population: * those who are allergic to any component of the medicine; * active bleeding; * active peptic ulcer; * hypertension not controlled by drugs; * those with severe liver insufficiency. 2. medical conditions that affect absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.); 3. patients with a clear past history of neurological or psychiatric disorders; 4. the patient had been treated with another study drug or study device in the 4 weeks prior to initial dosing; 5. pregnant or breastfeeding women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures; 6. unable to follow the research protocol for treatment or scheduled follow-up; 7. any other researcher who thinks they cannot be included.
preterm newborn's behavioral responses during feeding with gastric tube

Conditions: Premature Birth

Summary: preterm infants need aims of a tube named oral or naso gastric to grow until they acquire autonomy in suction-swallowing. in fact, several modes feed by a gastric tube exist : using an electric syringe pump (continuous administration), or manual and individualization administration. in this second case, milk can be delivered by gravity, depending on the height the syringe is placed above the infant, or by manually pushing on the syringe. milk can be administrated by nurses or by the parents after a learning period. in this observational study, we would like to compare the preterm infants' behavioral during these different naso or oro gastric feeding modes by observing well-being signs and withdrawal signs (dsilna grid) on video settings.


Eligibility criteria:
inclusion criteria: * hospitalized at the university hospitals of strasbourg during october 2024 and october 2025 * needing nasogastric tube feeding during at least 4 days * with parents (legal representants) having expressed their agreement with the use of video recording in the framework of the current study exclusion criteria: * orl malformations * neurological dysfunction * sedated infant

Keywords: preterm infants oro/nasogastric tube feeding developmental care parents integration
safety and performance of the zeus cc stent for the treatment of iliac occlusive disease

Conditions: Peripheral Artery Disease

Summary: the purpose of this study is to evaluate safety and performance of the balloon-expandable zeus cc (rontis ag) stent for the treatment of trans-atlantic inter-society consensus (tasc) a, b, c and d iliac lesions.


Eligibility criteria:
inclusion criteria: 1. patient is older than 18 years 2. patient must sign a written informed consent form that is approved by the ethics committee prior to index-procedure 3. patient must be compliant with all follow-up visits 4. patient suffers from intermittent claudication (rutherford 1-3) or critical limb ischemia (rutherford 4 and 5) 5. patient's life expectancy is more than 2 years 6. patient has iliac atherosclerotic de novo lesion(s) type a, b, c \& d according to tasc-ii classification 7. target vessel diameter is between 5 and 9 mm 8. target lesion has a baseline diameter stenosis of more than 50% 9. patient has sufficient infra-inguinal run-off with at least a patent common femoral artery and deep femoral artery (both \<50% stenosis) exclusion criteria: 1. patient has a life expectancy of less than 2 years 2. patient is refusing to be compliant with all follow-up visits 3. patient suffers from acute limb ischemia, defined as any sudden decrease in limb perfusion causing a potential threat to limb viability. 4. patient is intolerant to anticoagulant or antiplatelet therapy such as aspirin, heparin, clopidogrel or ticlopidine drug therapy 5. patient has already been treated with a stent in the ipsilateral target vessel 6. patient suffered tissue loss in the target extremities, defined as rutherford 6 7. patient is already enrolled in this or another investigational device study 8. patient had a coronary intervention within the last 60 days before enrolment into this study or there is a planned coronary intervention within 60 days of enrolment into this study 9. use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index-procedure 10. any planned surgical intervention within 30 days of the index-procedure 11. patient has an abdominal aortic aneurysm that is likely to require repair within the next 2 years. 12. patient has no sufficient infra-inguinal run-off (\>50% stenosis). patient inclusion is only possible if revascularization (endovascular or surgical) is performed in the same procedure with a peroperative angiographic control yielding \<30% stenosis. 13. target lesion is a restenotic lesion. 14. target lesion is adjacent an aneurysm. 15. target vessel perforation with documented contrast extravasation during index-procedure prior to stent placement.

Keywords: stent therapy
magnetic resonance (mr) imaging to determine high risk areas in patients with malignant gliomas and to design potential radiation plans and to examine metabolite changes in gliomas and other solid tumors

Conditions: Brain Cancer; Glioma

Summary: the researchers think that the use of advanced mr imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. wethe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.


Eligibility criteria:
inclusion criteria: * suspected or histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (idh) mutation * may undergo radiation therapy * patient and/or guardian is able to provide written informed consent prior to study registration * age ≥ 18 years old exclusion criteria: * extreme claustrophobia that precludes mri scan * known allergic reaction to gd-dtpa * any contraindication to gadolinium intravenous contrast as per standard department of radiology contrast guidelines * any absolute contraindication to mri (e.g., pacemaker, aneurysm clip, tissue expander). * pregnant or nursing female * unable to cooperate for mri and/or radiation therapy planning

Keywords: brain tumor radiation mri 09-009
the effect of therapeutic touch at birth on pain, birth duration, traumatic birth perception and anxiety

Conditions: Pregnancy; Vaginal Delivery

Summary: aim: this study was planned to determine the effect of therapeutic touch applied at birth on pain, birth duration, traumatic birth perception and anxiety.

methods: the sample of this randomized controlled experimental research consisted of 66 (intervention group: 33; control group: 33) women. data were collected using a personal information form, visual analogue scale, state anxiety inventory and traumatic childbirth perception scale.

Eligibility criteria:
inclusion criteria: not having a high-risk pregnancy having no health problems with the baby or herself having a single foetus being about to have a vaginal delivery not having a chronic physical or psychiatric diagnosis agreeing to participate in the research not having communication and perception problems miad (37w\<) pregnancy having with induction application exclusion criteria: having vacuum, forceps etc. intervention such as

Keywords: therapeutic touch labor pain birth duration anxiety traumatic birth perception